Yahoo Finance

Tucked into the bipartisan budget deal that President-elect Donald Trump’s allies torpedoed earlier this month was a rare and significant attempt to reform the mechanics of America’s drug-pricing system. Americans are broadly aware of how big pharma profits from high drug prices, but few understand the market distortions introduced by pharmacy benefit management (PBM) companies that negotiate prices on behalf of employers, insurers and government programs.